-
- Enrique Grande
- Department of Medical Oncology, Ramón y Cajal University Hospital, 28034 Madrid, Spain
-
- Juan José Díez
- Department of Endocrinology, Ramón y Cajal University Hospital, 28034 Madrid, Spain
-
- Carles Zafon
- Department of Endocrinology, Vall d’Hebron University Hospital, 08035 Barcelona, Spain
-
- Jaume Capdevila
- Department of Medical Oncology, Vall d’Hebron University Hospital, 08035 Barcelona, Spain
説明
<jats:p>Despite that thyroid cancer accounts for over 90% of tumors that arise from the endocrine system, these tumors barely represent 2% of solid tumors in adults. Many entities are grouped under the general term of thyroid cancer, and they differ in histological features as well as molecular and clinical behavior. Thus, the prognosis for patients with thyroid cancer ranges from a survival rate of >97% at 5 years, in the case of differentiated thyroid tumors sensitive to radioactive iodine, to a 4-month median survival for anaplastic tumors. The high vascularity in these tumors and the important role that oncogenic mutations may have in the RAS/RAF/MEK pathway and oncogenicity (as suggested by activating mutations and rearrangements of the<jats:italic>RET</jats:italic>gene) have led to the development of multitarget inhibitors in different histological subgroups of patients. The correct molecular characterization of patients with thyroid cancer is thought to be a key aspect for the future clinical management of these patients.</jats:p>
収録刊行物
-
- Journal of Thyroid Research
-
Journal of Thyroid Research 2012 1-10, 2012
Hindawi Limited
